From the hope to the ontarget and the transcend studies: challenges in improving prognosis
Data up to Jan 2025
Total Citations Per Year
Abstract
References (13)
Effects of an Angiotensin-Converting–Enzyme Inhibitor, Ramipril, on Cardiovascular Events in High-Risk Patients
2000 • 8,612 citations
A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart Failure
2001 • 3,065 citations
Major Cardiovascular Events in Hypertensive Patients Randomized to Doxazosin vs Chlorthalidone: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
2000 • 1,451 citations
Comparison of Candesartan, Enalapril, and Their Combination in Congestive Heart Failure
1999 • 898 citations
Tissue Angiotensin and Pathobiology of Vascular Disease
2001 • 750 citations
Effects of Ramipril and Vitamin E on Atherosclerosis
2001 • 726 citations
The role of the renin-angiotensin system in the development of cardiovascular disease
2002 • 510 citations
Increased Accumulation of Tissue ACE in Human Atherosclerotic Coronary Artery Disease
1996 • 431 citations
Major cardiovascular events in hypertensive patients randomized to doxazosin versus chlorthalidone
2000 • 87 citations
Angiotensin II and trials of cardiovascular outcomes11Reprints are not available.
2002 • 75 citations
Inhibiting Renin-Angiotensin in the Brain: the Possible Therapeutic Implications
2001 • 23 citations
Rationale and pharmacology of angiotensin II receptor antagonists: current status and future issues.
1997 • 21 citations
Angiotensin II receptor antagonists in the treatment of hypertension.
1999 • 14 citations